{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:19:44Z","timestamp":1769005184849,"version":"3.49.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2017-0110_s_999_w2aab3b7c25b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Vasopressin and adrenomedullin and their stable by-products copeptin and midregional part of proadrenomedullin (MR-proADM) are promising biomarkers for the development of preeclampsia. However, clinical use is hampered by the lack of trimester-specific reference intervals. We therefore estimated reference intervals for copeptin and MR-proADM in disease-free Dutch women throughout pregnancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0110_s_998_w2aab3b7c25b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Apparently healthy low risk pregnant women were recruited. Exclusion criteria included current or past history of endocrine disease, multiple pregnancy, use of medication known to influence thyroid function and current pregnancy as a result of hormonal stimulation. Women who miscarried, developed hyperemesis gravidarum, hypertension, pre-eclampsia, hemolysis elevated liver enzymes and low platelets, diabetes or other disease, delivered prematurely or had a small for gestational age neonate were excluded from analyses. Blood samples were collected at 9\u201313 weeks (n=98), 27\u201329 weeks (n=94) and 36\u201339 weeks (n=91) of gestation and at 4\u201313 weeks post-partum (PP) (n=89). Sixty-two women had complete data during pregnancy and PP. All analyses were performed on a Kryptor compact plus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0110_s_997_w2aab3b7c25b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Copeptin increases during pregnancy, but 97.5th percentiles remain below the non-pregnant upper reference limit (URL) provided by the manufacturer. MR-proADM concentrations increase as well during pregnancy. In trimesters 2 and 3 the 97.5th percentiles are over three times the non-pregnant URL provided by the manufacturer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0110_s_996_w2aab3b7c25b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Trimester- and assay-specific reference intervals for copeptin and MR-proADM should be used. In addition, consecutive measurements and the time frame between measurements should be considered as the differences seen with or in advance of preeclampsia can be expected to be relatively small compared to the reference intervals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2017-0110","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T07:53:57Z","timestamp":1499068437000},"page":"113-119","source":"Crossref","is-referenced-by-count":13,"title":["Reference intervals and longitudinal changes in copeptin and MR-proADM concentrations during pregnancy"],"prefix":"10.1515","volume":"56","author":[{"given":"Annemiek M.C.P.","family":"Joosen","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Chemistry and Haematology , Franciscus Gasthuis and Vlietland , Kleiweg 500 , 3045 PM Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivon J.M.","family":"van der Linden","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Haematology , Amphia Hospital , Breda , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne","family":"Schrauwen","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Haematology , Amphia Hospital , Breda , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisia","family":"Theeuwes","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Haematology , Elisabeth-TweeSteden Hospital , Tilburg , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique J.M.","family":"de Groot","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Haematology , Amphia Hospital , Breda , The Netherlands"},{"name":"Laboratory of Clinical Chemistry and Haematology , Elisabeth-TweeSteden Hospital , Tilburg , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonius A.M.","family":"Ermens","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Haematology , Amphia Hospital , Breda , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"key":"2021021219455077018_j_cclm-2017-0110_ref_001_w2aab3b7c25b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens 2014;4:97\u2013104.","DOI":"10.1016\/j.preghy.2014.02.001"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_002_w2aab3b7c25b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet 2010;376:631\u201344.","DOI":"10.1016\/S0140-6736(10)60279-6"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_003_w2aab3b7c25b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Kar M. Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res 2014;8:BE01\u20134.","DOI":"10.7860\/JCDR\/2014\/7969.4261"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_004_w2aab3b7c25b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Melchiorre K, Sharma R, Thilaganathan B. Cardiovascular implications in preeclampsia: an overview. Circulation 2014;130:703\u201314.","DOI":"10.1161\/CIRCULATIONAHA.113.003664"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_005_w2aab3b7c25b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Ghossein-Doha C, Khalil A, Lees CC. Maternal hemodynamics: a 2017 update. Ultrasound Obstet Gynecol 2017;49:10\u201314.","DOI":"10.1002\/uog.17377"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_006_w2aab3b7c25b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Santillan MK, Santillan DA, Scroggins SM, Min JY, Sandgren JA, Pearson NA, et al. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension 2014;64:852\u20139.","DOI":"10.1161\/HYPERTENSIONAHA.114.03848"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_007_w2aab3b7c25b1b6b1ab2b2b7Aa","unstructured":"Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138\u201367."},{"key":"2021021219455077018_j_cclm-2017-0110_ref_008_w2aab3b7c25b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823\u20139.","DOI":"10.1373\/clinchem.2005.051110"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_009_w2aab3b7c25b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Birdir C, Janssen K, Stanescu AD, Enekwe A, Kasimir-Bauer S, Gellhaus A, et al. Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia. Arch Gynecol Obstet 2015;292:1033\u201342.","DOI":"10.1007\/s00404-015-3745-7"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_010_w2aab3b7c25b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Santillan M, Santillan D, Scroggins S, Min J, Leslie K, Hunter S, et al. Vasopressin secretion in human pregnancy predicts the development of preeclampsia as early as the sixth week of gestation. Pregnancy Hypertens 2015;5:25\u20136.","DOI":"10.1016\/j.preghy.2014.10.053"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_011_w2aab3b7c25b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Sugulle M, Herse F, Seiler M, Dechend R, Staff AC. Cardiovascular risk markers in pregnancies complicated by diabetes mellitus or preeclampsia. Pregnancy Hypertens 2012;2:403\u201310.","DOI":"10.1016\/j.preghy.2012.03.002"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_012_w2aab3b7c25b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Tuten A, Oncul M, Kucur M, Imamoglu M, Ekmekci OB, Ac\u0131kgoz AS, et al. Maternal serum copeptin concentrations in early- and late-onset pre-eclampsia. Taiwan J Obstet Gynecol 2015;54:350\u20134.","DOI":"10.1016\/j.tjog.2013.10.045"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_013_w2aab3b7c25b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Wellmann S, Benzing J, Fleischlin S, Morgenthaler N, Fouzas S, B\u00fchrer CA, et al. Cardiovascular biomarkers in preeclampsia at triage. Fetal Diagn Ther 2014;36:202\u20137.","DOI":"10.1159\/000361016"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_014_w2aab3b7c25b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Yeung EH, Liu A, Mills JL, Zhang C, M\u00e4nnist\u00f6 T, Lu Z, et al. Increased levels of copeptin before clinical diagnosis of preelcampsia. Hypertension 2014;64:1362\u20137.","DOI":"10.1161\/HYPERTENSIONAHA.114.03762"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_015_w2aab3b7c25b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res 2011;37:1198\u2013202.","DOI":"10.1111\/j.1447-0756.2010.01498.x"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_016_w2aab3b7c25b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Solberg HE. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin Chem Lab Med 2004;42:710\u20134.","DOI":"10.1515\/CCLM.2004.121"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_017_w2aab3b7c25b1b6b1ab2b2c17Aa","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Defining, establishing and verifying reference intervals in the clinical laboratory. Approved guideline. 3rd ed. 2008, C28-A3c."},{"key":"2021021219455077018_j_cclm-2017-0110_ref_018_w2aab3b7c25b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112\u20139.","DOI":"10.1373\/clinchem.2005.060038"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_019_w2aab3b7c25b1b6b1ab2b2c19Aa","unstructured":"B\u00fclb\u00fcl GA, Kumru S, Erol O, Isenlik BS, Ozdemir O, Ca\u011flar M, et al. Maternal and umbilical cord copeptin levels in pregnancies complicated by fetal growth restriction. J Matern Fetal Neonatal Med 2014;18:1\u20137."},{"key":"2021021219455077018_j_cclm-2017-0110_ref_020_w2aab3b7c25b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Foda AA, Abdel Aal IA. Maternal and neonatal copeptin levels at cesarean section and vaginal delivery. Eur J Obstet Gynecol Reprod Biol 2012;165:215\u20138.","DOI":"10.1016\/j.ejogrb.2012.08.012"},{"key":"2021021219455077018_j_cclm-2017-0110_ref_021_w2aab3b7c25b1b6b1ab2b2c21Aa","unstructured":"Senna AA, Zedan M, el-Salam GE, el-Mashad AI. Study of plasma adrenomedullin level in normal pregnancy and preclampsia. Medscape J Med 2008;10:29."},{"key":"2021021219455077018_j_cclm-2017-0110_ref_022_w2aab3b7c25b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Matson BC, Corty RW, Karpinich NO, Murtha AP, Valdar W, Grotegut CA, et al. Midregional pro-adrenomedullin plasma concentrations are blunted in severe preeclampsia. Placenta 2014;35:780\u20133.","DOI":"10.1016\/j.placenta.2014.07.003"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2018.56.issue-1\/cclm-2017-0110\/cclm-2017-0110.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0110\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:57:31Z","timestamp":1619049451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0110\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,6,16]]},"published-print":{"date-parts":[[2017,11,27]]}},"alternative-id":["10.1515\/cclm-2017-0110"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2017-0110","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,16]]}}}